Toxicities From Antibody-Drug Conjugates

被引：3
|
作者：
Johns, Andrew C. [1 ,3 ]
Campbell, Matthew T. [1 ,2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
[3] MD Anderson Canc Ctr, Unit 1374, Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
来源：
CANCER JOURNAL | 2022年 / 28卷 / 06期
关键词：
Antibody-drug conjugate; management; toxicity; OPEN-LABEL; BRENTUXIMAB VEDOTIN; SINGLE-ARM; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; INOTUZUMAB OZOGAMICIN; HODGKIN-LYMPHOMA; OLDER PATIENTS; BROAD RANGE; STAGE-III;
D O I：
10.1097/PPO.0000000000000626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antibody-drug conjugates are becoming increasingly important in the treatment of many cancer types. The 3 main structural components-antibody, linker, and payload-each contribute to the toxicity profiles of these drugs. In addition to cytopenias and gastrointestinal adverse effects attributed to the chemotherapy payloads, each drug has specific toxicities that are not commonly described in oncology. Ocular, pulmonary, dermatologic, and neurologic toxicities are particularly nuanced. This review provides a framework for clinicians to analyze current and future antibody-drug conjugates and a description of the unique monitoring, preventive, and supportive care measures for these agents.
引用
收藏
页码：469 / 478
页数：10
相关论文
共 50 条
  • [1] Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
    Donaghy, Heather
    MABS, 2016, 8 (04) : 659 - 671
  • [2] Acquired Resistance to Antibody-Drug Conjugates
    Collins, Denis M.
    Bossenmaier, Birgit
    Kollmorgen, Gwendlyn
    Niederfellner, Gerhard
    CANCERS, 2019, 11 (03):
  • [3] Antibody-Drug Conjugates: The Last Decade
    Joubert, Nicolas
    Beck, Alain
    Dumontet, Charles
    Denevault-Sabourin, Caroline
    PHARMACEUTICALS, 2020, 13 (09) : 1 - 30
  • [4] Resistance to Antibody-Drug Conjugates
    Garcia-Alonso, Sara
    Ocana, Alberto
    Pandiella, Atanasio
    CANCER RESEARCH, 2018, 78 (09) : 2159 - 2165
  • [5] Antibody-drug conjugates for cancer
    Chau, Cindy H.
    Steeg, Patricia S.
    Figg, William D.
    LANCET, 2019, 394 (10200) : 793 - 804
  • [6] Antibody-Drug Conjugates: Ushering in a New Era of Cancer Therapy
    Hurwitz, Joshua
    Haggstrom, Lucy Roxana
    Lim, Elgene
    PHARMACEUTICS, 2023, 15 (08)
  • [7] Dermatologic toxicities of antibody- drug conjugates
    Gronbeck, Christian
    Hadfield, Matthew J.
    Grant-Kels, Jane M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (06) : 1177 - 1188
  • [8] Antibody-Drug Conjugates for Cancer Therapy
    Hafeez, Umbreen
    Parakh, Sagun
    Gan, Hui K.
    Scott, Andrew M.
    MOLECULES, 2020, 25 (20):
  • [9] Antibody-Drug Conjugates in Bladder Cancer
    Vlachostergios, Panagiotis J.
    Jakubowski, Christopher D.
    Niaz, Muhammad J.
    Lee, Aileen
    Thomas, Charlene
    Hackett, Amy L.
    Patel, Priyanka
    Rashid, Naureen
    Tagawa, Scott T.
    BLADDER CANCER, 2018, 4 (03) : 247 - 259
  • [10] Antibody-Drug Conjugates in Cancer Therapy
    Sievers, Eric L.
    Senter, Peter D.
    ANNUAL REVIEW OF MEDICINE, VOL 64, 2013, 64 : 15 - 29
12345